Adverum Biotechnologies, Inc.
ADVM
$4.19
$0.020.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.65M | -49.19M | -47.02M | -60.53M | -32.35M |
| Total Depreciation and Amortization | 465.00K | 535.00K | 683.00K | 810.00K | 890.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.43M | 2.40M | 3.35M | 22.54M | 6.49M |
| Change in Net Operating Assets | 16.65M | 7.49M | 215.00K | 8.93M | 3.85M |
| Cash from Operations | -28.12M | -38.77M | -42.77M | -28.25M | -21.12M |
| Capital Expenditure | -142.00K | -120.00K | -220.00K | -61.00K | -221.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.00M | 32.02M | 31.50M | -4.13M | -13.13M |
| Cash from Investing | 1.86M | 31.90M | 31.28M | -4.19M | -13.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.90M | 120.00K | -- | 239.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9.90M | 120.00K | -- | 239.00K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.36M | -6.74M | -11.49M | -32.20M | -34.47M |